193 related articles for article (PubMed ID: 31251694)
1. Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial.
Koole SN; van Lieshout C; van Driel WJ; van Schagen E; Sikorska K; Kieffer JM; Schagen van Leeuwen JH; Schreuder HWR; Hermans RH; de Hingh IH; van der Velden J; Arts HJ; Massuger LFAG; Aalbers AG; Verwaal VJ; Van de Vijver KK; Aaronson NK; van Tinteren H; Sonke GS; van Harten WH; Retèl VP
J Clin Oncol; 2019 Aug; 37(23):2041-2050. PubMed ID: 31251694
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness Analysis of Cytoreductive Surgery and HIPEC Compared With Systemic Chemotherapy in Isolated Peritoneal Carcinomatosis From Metastatic Colorectal Cancer.
Hamilton TD; MacNeill AJ; Lim H; Hunink MGM
Ann Surg Oncol; 2019 Apr; 26(4):1110-1117. PubMed ID: 30690682
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPEC-01).
Kim JH; Chun SY; Lee DE; Woo YH; Chang SJ; Park SY; Chang YJ; Lim MC
Gynecol Oncol; 2023 Mar; 170():19-24. PubMed ID: 36608383
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy.
Lim SL; Havrilesky LJ; Habib AS; Secord AA
Gynecol Oncol; 2019 May; 153(2):376-380. PubMed ID: 30718126
[TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer.
Koole SN; Kieffer JM; K Sikorska ; Schagen van Leeuwen JH; Schreuder HWR; Hermans RH; de Hingh IH; van der Velden J; Arts HJ; van Ham MAPC; Aalbers AG; Verwaal VJ; Van de Vijver KK; Sonke GS; van Driel WJ; Aaronson NK
Eur J Surg Oncol; 2021 Jan; 47(1):101-107. PubMed ID: 31128948
[TBL] [Abstract][Full Text] [Related]
6. Early Cost-Effectiveness Analysis of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer Patients with Limited Peritoneal Carcinomatosis.
Verbeek JGE; van der Sluis K; Vollebergh MA; van Sandick JW; van Harten WH; Retèl VP
Pharmacoecon Open; 2024 Jan; 8(1):119-131. PubMed ID: 38032438
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial.
Aronson SL; Lopez-Yurda M; Koole SN; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; van Gent MDJM; Arts HJG; van Ham MAPC; van Dam PA; Vuylsteke P; Aalbers AGJ; Verwaal VJ; Van de Vijver KK; Aaronson NK; Sonke GS; van Driel WJ
Lancet Oncol; 2023 Oct; 24(10):1109-1118. PubMed ID: 37708912
[TBL] [Abstract][Full Text] [Related]
8. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S; van Stein R; Sikorska K; Barton D; Perrin L; Brennan D; Zivanovic O; Mosgaard BJ; Fagotti A; Colombo PE; Sonke G; Driel WJV;
Int J Gynecol Cancer; 2020 Jun; 30(6):888-892. PubMed ID: 32205449
[TBL] [Abstract][Full Text] [Related]
9. Cytoreductive surgery (CRS) with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) versus standard of care (SoC) in people with peritoneal metastases from colorectal, ovarian or gastric origin: protocol for a systematic review and individual participant data (IPD) meta-analyses of effectiveness and cost-effectiveness.
Gurusamy K; Vale CL; Pizzo E; Bhanot R; Davidson BR; Mould T; Mughal M; Saunders M; Aziz O; O'Dwyer S
BMJ Open; 2020 May; 10(5):e039314. PubMed ID: 32404398
[TBL] [Abstract][Full Text] [Related]
10. Central radiology assessment of the randomized phase III open-label OVHIPEC-1 trial in ovarian cancer.
Koole SN; Bruijs L; Fabris C; Sikorska K; Engbersen M; Schagen van Leeuwen JH; Schreuder HWR; Hermans RH; van der Velden J; Arts HJG; van Ham M; Van Dam P; Vuylsteke P; Lahaye M; Sonke G; Driel WV
Int J Gynecol Cancer; 2020 Dec; 30(12):1928-1934. PubMed ID: 33046576
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a community setting: A cost-utility analysis of a hospital's initial experience and reflections on the health care system.
Naffouje SA; O'Donoghue C; Salti GI
J Surg Oncol; 2016 Apr; 113(5):544-7. PubMed ID: 26750613
[TBL] [Abstract][Full Text] [Related]
12. Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery.
El Hajj H; Vanseymortier M; Hudry D; Bogart E; Abdeddaim C; Leblanc E; Le Deley MC; Narducci F
ESMO Open; 2021 Apr; 6(2):100098. PubMed ID: 33819750
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase.
Tran AQ; Erim DO; Sullivan SA; Cole AL; Barber EL; Kim KH; Gehrig PA; Wheeler SB
Gynecol Oncol; 2018 Feb; 148(2):329-335. PubMed ID: 29273308
[TBL] [Abstract][Full Text] [Related]
14. Cytoreduction (Peritonectomy Procedures) Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Advanced Ovarian Cancer: Retrospective Italian Multicenter Observational Study of 511 Cases.
Di Giorgio A; De Iaco P; De Simone M; Garofalo A; Scambia G; Pinna AD; Verdecchia GM; Ansaloni L; Macrì A; Cappellini P; Ceriani V; Giorda G; Biacchi D; Vaira M; Valle M; Sammartino P
Ann Surg Oncol; 2017 Apr; 24(4):914-922. PubMed ID: 27896512
[TBL] [Abstract][Full Text] [Related]
15. Cost-analysis of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with peritoneal malignancy: An Australian perspective with global application.
McBride KE; Steffens D; Solomon MJ; Koh C; Ansari N; Young CJ; Moran B
Eur J Surg Oncol; 2021 Apr; 47(4):828-833. PubMed ID: 32972815
[TBL] [Abstract][Full Text] [Related]
16. Hyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on.
Koole SN; van Driel WJ; Sonke GS
Cancer; 2019 Dec; 125 Suppl 24():4587-4593. PubMed ID: 31967678
[TBL] [Abstract][Full Text] [Related]
17. Effects of CytoReductive surgery plus hyperthermic IntraPEritoneal chemotherapy (HIPEC) versus CytoReductive surgery for ovarian cancer patients: A systematic review and meta-analysis.
Wang Y; Ren F; Chen P; Liu S; Song Z; Ma X
Eur J Surg Oncol; 2019 Mar; 45(3):301-309. PubMed ID: 30786961
[TBL] [Abstract][Full Text] [Related]
18. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis.
Huo YR; Richards A; Liauw W; Morris DL
Eur J Surg Oncol; 2015 Dec; 41(12):1578-89. PubMed ID: 26453145
[TBL] [Abstract][Full Text] [Related]
19. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer.
van de Vrie R; van Meurs HS; Rutten MJ; Naaktgeboren CA; Opmeer BC; Gaarenstroom KN; van Gorp T; Ter Brugge HG; Hofhuis W; Schreuder HWR; Arts HJG; Zusterzeel PLM; Pijnenborg JMA; van Haaften M; Engelen MJA; Boss EA; Vos MC; Gerestein KG; Schutter EMJ; Kenter GG; Bossuyt PMM; Mol BW; Buist MR
Gynecol Oncol; 2017 Sep; 146(3):449-456. PubMed ID: 28645428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
